We are seeking feedback on a proposal to fund a new modified-release granule formulation of pancreatic enzymes (Creon Micro), which is used for the treatment of pancreatic enzyme insufficiency, from 1 June 2020 through a provisional agreement with Mylan New Zealand Limited (Mylan).
Closes: 5pm Thursday 30 April 2020
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender, dated 1 November 2019.
PHARMAC is placing temporary dispensing limits on all funded community medicines from Friday 27 March 2020.
To give people more clarity about what medicines we are, or are not, actively considering for funding, we will be making more decisions on inactive applications.
PHARMAC is seeking feedback on a proposal about the frequency of dispensing of pharmaceuticals in the community.
We are proposing to amend the dispensing frequency rules and expand the list of pharmaceuticals that can be dispensed in a single lot. The purpose of the proposed changes is to enable greater flexibility in tailoring medicine supply to the needs of patients.
Consultation closes: 5pm Friday 17 April 2020.
PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by O&M Halyard Australia Pty Ltd in Part III of Section H of the Pharmaceutical Schedule from 1 June 2020.
Closes: 4pm Monday 13 April 2020.
PHARMAC is advising all interested parties that there is a further delay in the listing of a new funded brand of atomoxetine and removal of the current funding restrictions. The following reflects the most up-to-date information.
We are pleased to announce the approval of a listing agreement with Applied Medical New Zealand Limited for the supply of medical devices in the endomechanical and electrosurgical category.
We are pleased to announce the approval of a listing agreement with Mӧlnlycke Health Care Pty Ltd for the supply of rehabilitation equipment, patient positioning products and supports; and surgical drapes, gowns and procedure packs.
We are pleased to announce the approval of a listing agreement with Ultramedix Australasia Limited for the supply of obstetrics and gynaecology products to DHBs.
Background information on the medicine Zapril.
PHARMAC is seeking feedback on a proposal to list medical devices supplied by Paragon Care Group New Zealand Limited in Part III of Section H of the Pharmaceutical Schedule from 1 May 2020.
Closes: 4pm Thursday 2 April 2020.
Number of asthma inhalers dispensed in both the community and hospital settings (2014–2018)
Technical Assessment Reports (TAR) for pembrolizumab in advanced melanoma, as per the Feb 2016 PTAC minutes this is TAR No. 271.
Number of Mirena devices approved and dispensed.
Around 500 New Zealanders who have severe asthma will have access to a new medicine, mepolizumab, from next month.
Decision to fund mepolizumab (Nucala) for the treatment of patients with severe refractory eosinophilic asthma
We are pleased to announce a decision to fund mepolizumab (Nucala) from 1 April 2020 for the treatment of severe refractory eosinophilic asthma, through an agreement with GlaxoSmithKline NZ Limited (GSK).
We are pleased to announce the approval of listing agreements for the supply of rehabilitation equipment, patient positioning products and supports with Active Healthcare (NZ) Limited; Allied Medical Limited; Amtech Medical Limited; and Permobil New Zealand Limited.
We're pleased to announce a decision to widen funded access to lenalidomide (Revlimid) to include maintenance treatment for people with newly diagnosed multiple myeloma (a type of blood cancer) who have undergone autologous stem cell transplant (auto-SCT), through an agreement with Celgene Pty Limited.
We are pleased to announce the approval of a decision to fund a new topical psoriasis medicine, betamethasone dipropionate with calcipotriol foam spray (Enstilar) from 1 April 2020, through a listing agreement with Leo Pharma.